Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype
- 1 July 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 10 (5) , 453-460
- https://doi.org/10.1097/00008571-200007000-00008
Abstract
Paraoxonase (PON1) is tightly associated with high-density lipoprotein particles and is believed to contribute to the prevention of atherosclerosis by metabolizing oxidized lipids. PON1 also hydrolyses the bioactive oxon forms of organophosphorus pesticides such as parathion, diazinon and chlorpyrifos. Two common polymorphisms have been identified in the coding sequence of human PON1: L55M and R192Q. Several previous studies have found that the presence of the PON1 R192 allele raises the risk of cardiovascular disease while others found no correlation. The studies, however, have focused on the genotype of PON1 and not the expression level of the protein. We found that the PON1 expression level in plasma, as determined by the rates of paraoxon and diazoxon hydrolysis, varies widely among individuals and within a genotype. Previous studies found that individuals having Met at PON155 have lower levels of both PON1 mRNA and activity. In this study, we determined the plasma activity levels of PON1 and examined the relationships between PON1 55 genotype and PON1 level. As with PON1 192, we found considerable overlap in activity among the PON1 55 genotypes. Of the 317 individuals whose PON1 status was determined in this study, 48.9% were PON1 Q192 homozygotes. Analysis of the PON1QQ192 population showed that while the average PON1 activity (diazoxon hydrolysis) was 12266 U/L for PON1LL55 and 7777 U/L for PON1MM55, a given PON1MM55 individual could have more than twice the activity of a PON1LL55 individual. PON1 status, which includes PON1 level as well as PON1 192 genotype, may be a better predictor for cardiovascular disease or organophosphate susceptibility than PON1 genotype alone.Keywords
This publication has 41 references indexed in Scilit:
- Acute and reversible parkinsonism due to organophosphate pesticide intoxicationNeurology, 1999
- Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase.Journal of Clinical Investigation, 1998
- Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.Journal of Clinical Investigation, 1997
- The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarinNature Genetics, 1996
- The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns.Journal of Clinical Investigation, 1996
- Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrationsBiochemical Journal, 1994
- Human and rabbit paraoxonases: Purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxificationChemico-Biological Interactions, 1993
- Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesteraseAnalytical Biochemistry, 1989
- A‐esterase activities in relation to the differential toxicity of pirimiphos‐methyl to birds and mammalsPesticide Science, 1980
- POSSIBLE ORGANOPHOSPHATE-INDUCED PARKINSONISMJournal of Nervous & Mental Disease, 1978